Scientists develop cross-species coronavirus test

Del­phia Ther­a­peu­tics said Thurs­day that it raised $67 mil­lion to de­vel­op tar­get­ed can­cer ther­a­pies that over­ac­ti­vate dri­vers of can­cer, de­fy­ing the norm es­tab­lished by decades

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured loan facility with Oxford Finance. Image